UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5464-5473

2005

Volltextzugriff (PDF)

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3771-3779

2001

Volltextzugriff (PDF)

High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency

Journal of clinical oncology, 1997-02, Vol.15 (2), p.833-839

1997

Volltextzugriff (PDF)

Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1021-1021

2010

Volltextzugriff (PDF)

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Journal of clinical oncology, 2005-02, Vol.23 (4), p.792-799

2005

Volltextzugriff (PDF)

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5474-5483

2005

Volltextzugriff (PDF)

Clinical performance, efficacy, and safety of the DigniCap system, a scalp-hypothermia system, in preventing chemotherapy (CTX)-induced alopecia in patients (pts) with early-stage breast cancer (BC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS244-TPS244

2011

Volltextzugriff (PDF)

Number needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.581-581

2009

Volltextzugriff (PDF)

Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.583-583

2007

Volltextzugriff (PDF)

Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts)

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.13-13

2011

Volltextzugriff (PDF)

A semi-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.605-605

2011

Volltextzugriff (PDF)

A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS110-TPS110

2011

Volltextzugriff (PDF)

Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1010-1010

2011

Volltextzugriff (PDF)

Letrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early stage breast cancer: Using number needed to treat (NNT) to compare benefit

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.17547-17547

2008

Volltextzugriff (PDF)

Factors impacting survival after diagnosis of breast cancer (BC) brain metastases (BM)

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.31-31

2011

Volltextzugriff (PDF)

Bevacizumab (BEV) plus second-line taxane (TAX) or other chemotherapy (CT) for triple-negative breast cancer (TNBC): Subgroup analysis of RIBBON-2

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.290-290

2011

Volltextzugriff (PDF)

A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1- amplified and nonamplified metastatic breast cancer (BC)

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.289-289

2011

Volltextzugriff (PDF)

Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC)

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.9-9

2011

Volltextzugriff (PDF)

A phase I dose and exposure escalation study of 5-day intermittent oral lapatinib (Lp) therapy in patients with HER2-overexpressing breast cancer (BC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11077-e11077

2011

Volltextzugriff (PDF)

Sunitinib as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1094-1094

2011

Volltextzugriff (PDF)

Comparison of patient-reported symptoms and health behaviors to clinician documentation among patients with breast cancer in follow-up care

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.9133-9133

2011

Volltextzugriff (PDF)

Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1002-1002

2010

Volltextzugriff (PDF)

Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.579-579

2010

Volltextzugriff (PDF)

Timing in adjuvant chemotherapy (CTX) initiation among women with breast cancer (BC) at National Comprehensive Cancer Network (NCCN) centers: An analysis from the NCCN Outcomes Database

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6022-6022

2011

Volltextzugriff (PDF)

Cardiovascular safety of adjuvant bevacizumab for breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.571-571

2010

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(117)

Publikationsform

Artikel
(118)

Sprache

Englisch
(118)
Japanisch
(3)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency

Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC)

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Clinical performance, efficacy, and safety of the DigniCap system, a scalp-hypothermia system, in preventing chemotherapy (CTX)-induced alopecia in patients (pts) with early-stage breast cancer (BC)

Number needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC)

Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS)

Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts)

A semi-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC

A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer

Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2

Letrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early stage breast cancer: Using number needed to treat (NNT) to compare benefit

Factors impacting survival after diagnosis of breast cancer (BC) brain metastases (BM)

Bevacizumab (BEV) plus second-line taxane (TAX) or other chemotherapy (CT) for triple-negative breast cancer (TNBC): Subgroup analysis of RIBBON-2

A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1- amplified and nonamplified metastatic breast cancer (BC)

Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC)

A phase I dose and exposure escalation study of 5-day intermittent oral lapatinib (Lp) therapy in patients with HER2-overexpressing breast cancer (BC)

Sunitinib as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow

Comparison of patient-reported symptoms and health behaviors to clinician documentation among patients with breast cancer in follow-up care

Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results

Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC)

Timing in adjuvant chemotherapy (CTX) initiation among women with breast cancer (BC) at National Comprehensive Cancer Network (NCCN) centers: An analysis from the NCCN Outcomes Database

Cardiovascular safety of adjuvant bevacizumab for breast cancer

Aktive Filter

Suchergebnisse filtern